| Primary |
| Drug Use For Unknown Indication |
44.8% |
| Stent Placement |
9.3% |
| Hypertension |
6.2% |
| Product Used For Unknown Indication |
4.5% |
| Myocardial Infarction |
4.4% |
| Coronary Artery Disease |
3.3% |
| Acute Coronary Syndrome |
3.3% |
| Prophylaxis |
2.6% |
| Cerebrovascular Accident |
2.3% |
| Angina Pectoris |
2.3% |
| Thrombosis Prophylaxis |
2.3% |
| Coronary Arterial Stent Insertion |
1.9% |
| Cerebral Infarction |
1.9% |
| Transient Ischaemic Attack |
1.8% |
| Acute Myocardial Infarction |
1.8% |
| Angina Unstable |
1.7% |
| Percutaneous Coronary Intervention |
1.6% |
| Diabetes Mellitus |
1.4% |
| Atrial Fibrillation |
1.4% |
| Hyperlipidaemia |
1.2% |
|
| Death |
28.1% |
| Gastrointestinal Haemorrhage |
7.9% |
| Myocardial Infarction |
7.3% |
| Haemorrhage |
6.3% |
| Thrombosis |
5.2% |
| Weight Decreased |
4.3% |
| Transient Ischaemic Attack |
4.2% |
| Vomiting |
4.1% |
| Cerebrovascular Accident |
4.0% |
| Thrombosis In Device |
3.8% |
| Thrombotic Thrombocytopenic Purpura |
3.0% |
| Rectal Haemorrhage |
2.9% |
| Pneumonia |
2.6% |
| Thrombocytopenia |
2.6% |
| Ulcer Haemorrhage |
2.5% |
| Pyrexia |
2.5% |
| Off Label Use |
2.3% |
| Rhabdomyolysis |
2.2% |
| International Normalised Ratio Increased |
2.1% |
| Pulmonary Embolism |
2.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
27.4% |
| Product Used For Unknown Indication |
12.5% |
| Stent Placement |
8.9% |
| Hypertension |
8.3% |
| Myocardial Infarction |
6.9% |
| Coronary Artery Disease |
4.3% |
| Atrial Fibrillation |
3.4% |
| Thrombosis Prophylaxis |
3.3% |
| Acute Coronary Syndrome |
3.3% |
| Prophylaxis |
2.9% |
| Acute Myocardial Infarction |
2.5% |
| Angina Pectoris |
2.2% |
| Percutaneous Coronary Intervention |
2.2% |
| Coronary Arterial Stent Insertion |
2.1% |
| Diabetes Mellitus |
2.0% |
| Pain |
1.7% |
| Hyperlipidaemia |
1.6% |
| Angina Unstable |
1.5% |
| Cerebrovascular Accident |
1.5% |
| Cardiac Disorder |
1.4% |
|
| Myocardial Infarction |
9.3% |
| Thrombocytopenia |
7.4% |
| Thrombosis In Device |
7.4% |
| Gastrointestinal Haemorrhage |
6.8% |
| Transient Ischaemic Attack |
6.8% |
| Weight Decreased |
6.7% |
| Vomiting |
6.4% |
| Haemorrhage |
6.3% |
| Rectal Haemorrhage |
4.6% |
| Thrombosis |
4.1% |
| Death |
4.0% |
| Interstitial Lung Disease |
3.8% |
| Melaena |
3.6% |
| Rash |
3.6% |
| Renal Failure Acute |
3.6% |
| Contusion |
3.5% |
| Overdose |
3.4% |
| Upper Gastrointestinal Haemorrhage |
3.0% |
| Epistaxis |
2.9% |
| Off Label Use |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.8% |
| Drug Use For Unknown Indication |
18.0% |
| Hypertension |
10.2% |
| Diabetes Mellitus |
3.9% |
| Cardiac Disorder |
3.6% |
| Blood Cholesterol Increased |
3.6% |
| Pain |
2.9% |
| Type 2 Diabetes Mellitus |
2.4% |
| Rheumatoid Arthritis |
2.4% |
| Prophylaxis |
2.2% |
| Depression |
2.1% |
| Osteoporosis |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Coronary Artery Disease |
1.5% |
| Anticoagulant Therapy |
1.4% |
| Atrial Fibrillation |
1.3% |
| Myocardial Infarction |
1.3% |
| Anxiety |
1.2% |
| Blood Pressure |
1.1% |
|
| Myocardial Infarction |
11.4% |
| Vomiting |
10.3% |
| Weight Decreased |
8.4% |
| Flushing |
6.9% |
| Weight Increased |
5.6% |
| Nausea |
5.3% |
| Pain |
5.0% |
| Pruritus |
4.7% |
| Drug Ineffective |
4.7% |
| Death |
4.3% |
| Pneumonia |
3.8% |
| Transient Ischaemic Attack |
3.6% |
| Dyspnoea |
3.6% |
| Cerebrovascular Accident |
3.6% |
| Renal Failure |
3.5% |
| Pain In Extremity |
3.3% |
| Vision Blurred |
3.1% |
| Renal Failure Acute |
3.1% |
| Tremor |
3.0% |
| Urinary Tract Infection |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
19.8% |
| Drug Use For Unknown Indication |
17.3% |
| Myocardial Infarction |
8.4% |
| Atrial Fibrillation |
6.6% |
| Acute Coronary Syndrome |
6.3% |
| Hypertension |
5.9% |
| Stent Placement |
4.5% |
| Acute Myocardial Infarction |
4.1% |
| Prophylaxis |
4.0% |
| Angina Pectoris |
3.6% |
| Gastrooesophageal Reflux Disease |
3.2% |
| Cerebrovascular Accident Prophylaxis |
2.3% |
| Myocardial Ischaemia |
2.0% |
| Pain |
1.9% |
| Cardiac Disorder |
1.8% |
| Cardiac Failure |
1.7% |
| Diabetes Mellitus |
1.7% |
| Type 2 Diabetes Mellitus |
1.6% |
| Dyspepsia |
1.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.6% |
|
| Drug Interaction |
36.2% |
| Myocardial Infarction |
7.6% |
| Gastrointestinal Haemorrhage |
5.7% |
| Hepatitis Cholestatic |
4.3% |
| Melaena |
4.3% |
| Haemorrhage |
3.8% |
| International Normalised Ratio Increased |
3.8% |
| Rhabdomyolysis |
3.3% |
| Transient Ischaemic Attack |
3.3% |
| Drug Ineffective |
2.9% |
| Petechiae |
2.9% |
| Shock Haemorrhagic |
2.9% |
| Staphylococcal Infection |
2.9% |
| Vomiting |
2.9% |
| Cerebrovascular Accident |
2.4% |
| Gastric Ulcer |
2.4% |
| Rectal Haemorrhage |
2.4% |
| Thrombosis |
2.4% |
| Contusion |
1.9% |
| Glycosylated Haemoglobin Increased |
1.9% |
|
